Videos

Vikram M. Narayan, MD, discusses how smoking is the most significant known risk factor for bladder cancer.

Reza Z. Goharderakhshan, MD, discusses how patient compliance for recommended studies increased from less than 10% to 82% following implementation of the program.

“Listen. Be emphatic. Be transparent,” Pansy Uberoi, MD, MPH, advises in this interview.

Urologist Adam J. Gadzinski, MD, MS, shares his excitement about the dawn of the precision medicine era in prostate cancer.

Over 90% of patients in a phase 2 trial had at least some decrease in the size of target lesions.

Victoria S. Edmonds and Tobias Köhler, MD, MPH, discuss trends in reimbursement for men's health procedures from 2002 to 2020.

The comprehensive review includes key developments in both clear cell and non-clear cell histology.

Gomella looks back on the year's top headlines in bladder cancer, from FDA approvals to notable clinical trial results.

Dr. Vikram M. Narayan describes treatment advances and next steps in non-muscle invasive bladder cancer.

Urologist Adam J. Gadzinski, MD, MS, shares how telemedicine can help improve access to urologic care.

Angela B. Smith, MD, MS, discusses how her institution has adjusted how it conducts clinical trials in the COVID-19 era.

The analyses are from a pivotal phase 3 trial of nadofaragene firadenovec which previously met its primary end point of complete response.

“As urologists, we all need to start speaking in risk stratification criteria,” says Katie Murray, DO.

Angela B. Smith, MD, MS, describes her institution’s early clinical experience with mitomycin-containing reverse thermal gel (Jelmyto).

Murray also discusses the low-grade upper tract urothelial cancer treatment mitomycin-containing reverse thermal gel (Jelmyto).

Dr. Declan G. Murphy discusses results from the phase 3 proPSMA study of Ga 68 PSMA-11 in patients with high-risk prostate cancer.